FTC Stretched Standards In Enforcement Against Bayer Probiotic Claim
This article was originally published in The Tan Sheet
Executive Summary
Judge Jose Linares states in his opinion that FTC’s requirement for “competent and reliable scientific evidence” to substantiate ad claims for consumer health care products aligns with FDA’s regulation of supplement claims under DSHEA, and Bayer complied with both agencies’ regs.
You may also be interested in...
Regulatory News In Brief
FTC/Garden of Life case continues; FDA deems ForMor in violation of GMPs; Kanebo faulted for pharmaceutical GMP failures; CytoSport settles litigation over Muscle Milk labeling; USPlabs’ carb claim canned in NAD review; FDA extends comment time on FSMA tracking pilots.
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.
MLM Group Not Buying FTC Executive’s Concerns About Its Income Disclosure Guidance
FTC Division of Marketing Practices assistant director concerned direct selling self-regulation group’s guidance “will encourage deceptive conduct and facilitate deceptive earnings claims.” DSA president says the concerns might reflect the thinking of agency’s staff more than the intent of the agency’s regulations.